SIU Events



Building on the success of the first GU Cancer Triad Meeting in 2019, SIU has convened a follow-up virtual meeting via SIU’s eLearning platform, SIU Academy. For two half days, world-renowned experts focused on the latest research in the top three GU cancers: bladder, kidney, and prostate. 

Event description

The treatment of genitourinary (GU) malignancies has seen tremendous revolution in recent years. Bladder cancer (BCa), renal cell carcinoma (RCC), and prostate cancer (PCa) are the most frequently encountered GU malignancies and represent a heterogeneous population of cancers, in both histology and approach to treatment. These three cancers continue to undergo major paradigm shifts in their respective therapeutic landscapes as we expand our understanding of their underlying molecular and oncogenic mechanisms.

The increasingly complex treatment landscape for bladder, kidney, and prostate cancers poses a challenge for urologists,medical oncologists, and radiation oncologists alike. In managing these GU cancers, physicians will need to keep up with new data on all treatment options, select therapies on an individual case basis, and use the optimal sequence or combinations while effectively managing side effects.

The topics presented during the B2B Meeting will enhance the audience’s understanding of the latest trends in diagnostic modalities and treatment approaches. It will include a discussion of the challenges and opportunities that new therapeutic approaches in these fields offer. In addition, this programme includes interactive panel discussions to facilitate understanding of how advances in diagnosis and treatment can best be integrated into patient care.

Learning Objectives

At the end of this programme, participants will be able to:

  • Evaluate the benefits and risks of various treatment options across the treatment continuum in BCa, RCC, and PCa.
  • Discuss strategies to identify and manage adverse events related to immunotherapy.
  • Evaluate the role of immunotherapy vs VEGF-targeted therapies for RCC.
  • Evaluate the role of imaging or biomarkers vs biopsy in active surveillance for localized prostate cancer.
  • Discuss strategies for managing oligometastatic disease.
  • Discuss the importance of personalized medicine, based on costs and patient preference, while minimizing toxicity and maximizing efficacy.

Click here to view the programme agenda. Click here to Meet the Faculty.


Curious about what's in store for this B2B meeting? Watch the short video below.


This meeting will be transmitted live on SIU Academy and webcasts will be available for on-demand viewing in January 2021. Keep the conversation going by sharing your thoughts and questions with colleagues on social media using #B2BGUCancerTriad




Looking to optimize your SIU 2020 B2B GU Cancer Triad Virtual Meeting experience? Watch this short video!







SIU 2024 Early Registration NOW OPEN
Follow Us